

Curriculum Vitae

Informazioni personali

Nome/ Cognome **Aldo Scarpa**
Indirizzo Anatomia Patologica Università di Verona
Telefono |
Fax |
E-mail aldo.scarpa@univr.it

Cittadinanza

Data di nascita

Sesso

Esperienze professionali

2016-oggi Direttore U.O.C. Anatomia e Istologia Patologica
Azienda Ospedaliera Universitaria Integrata di Verona

2010-2015 Direttore del Dipartimento di Patologia e Diagnostica, Università di Verona

2010-oggi Leader italiano del progetto "International Cancer Genome Consortium". La partecipazione italiana verte sui tumori pancreatici rari (Enteropancreatic endocrine tumors and rare pancreatic exocrine tumors).

2008-oggi Fondatore e Direttore del Centro Ricerca Applicata sul Cancro ARC-NET, Università di Verona

2004-oggi Professore Ordinario di Anatomia Patologica, Università di Verona

1992-2003 Professore Associato di Anatomia Patologica, Università di Verona
fs

Istruzione e formazione

Data 1989
Istituto di Istruzione Università di Verona
Qualifica conseguita Dottorato di Ricerca in Patologia Oncologica Umana

Data 1985
Istituto di Istruzione Università di Parma
Qualifica conseguita Specialità in Anatomia Patologica

Data 1980
Istituto di Istruzione Università di Padova
Qualifica conseguita Laurea in Medicina

Madrelingua Napoletano

Altre lingue Italiano: molto buono, scritto e parlato
Inglese: molto buono, scritto e parlato
Spagnolo: buono, parlato

Capacità e competenze personali

Campo di maggior esperienza

Anatomia patologica e Patologia Molecolare Oncologica

Capacità e competenze relazionali

Lo si chiede ai miei collaboratori

Capacità e competenze organizzative

Direttore unità operativa complessa e di centro di ricerca applicata sul cancro

Articoli recensiti da PubMed pubblicati negli ultimi due anni

Vedi allegato

Codice Fiscale

SCRLDA56H02F839Z

Il sottoscritto è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n. 445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal D. lgs. 196/03."

Firma

Verona, 16 giugno 2019

1. Vescovi R, Monti M, Moratto D, et al: Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. *Cancer Immunol Res* 7:12-28, 2019
2. Sorbye H, Baudin E, Borbath I, et al: Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). *Neuroendocrinology* 108:54-62, 2019
3. Obazee O, Archibugi L, Andriulli A, et al: Germline BRCA2 K3326X and CHEK2 I157T Mutations Increase Risk for Sporadic Pancreatic Ductal Adenocarcinoma. *Int J Cancer*, 2019
4. Maker AV, Hu V, Kadkol SS, et al: Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential. *J Am Coll Surg*, 2019
5. Mafficini A, Scarpa A: Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. *Endocr Rev*, 2019
6. Luchini C, Veronese N, Nottegar A, et al: Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. *Pancreas* 48:70-76, 2019
7. Lawlor RT, Veronese N, Nottegar A, et al: Prognostic Role of High-Grade Tumor Budding in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis with a Focus on Epithelial to Mesenchymal Transition. *Cancers (Basel)* 11, 2019
8. Lawlor RT, Dapra V, Girolami I, et al: CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas. *Virchows Arch* 474:105-109, 2019
9. Gomez-Rubio P, Pinero J, Molina-Montes E, et al: Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. *Int J Cancer* 144:1540-1549, 2019
10. Giordano G, Parcesepe P, D'Andrea MR, et al: JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. *J Exp Clin Cancer Res* 38:28, 2019
11. Giordano G, Olivieri N, D'Andrea MR, et al: Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report. *Oncol Lett* 17:462-467, 2019
12. Eccher A, Lombardini L, Girolami I, et al: How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network. *J Nephrol*, 2019
13. D'Onofrio M, Ciaravino V, Cardobi N, et al: CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms. *Sci Rep* 9:2176, 2019
14. Crino SF, Larghi A, Bernardoni L, et al: Touch imprint cytology on endoscopic ultrasound fine-needle biopsy provides comparable sample quality and diagnostic yield to standard endoscopic ultrasound fine-needle aspiration specimens in the evaluation of solid pancreatic lesions. *Cytopathology* 30:179-186, 2019
15. Beleu A, Calabrese A, Rizzo G, et al: Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. *Cancers (Basel)* 11, 2019
16. Armellini E, Manfrin E, Trisolini E, et al: Histologic retrieval rate of a newly designed side-bevelled 20G needle for EUS-guided tissue acquisition of solid pancreatic lesions. *United European Gastroenterol J* 7:96-104, 2019
17. Amato E, Mafficini A, Hirabayashi K, et al: Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. *J Pathol* 247:123-134, 2019
18. Yates LR, Seoane J, Le Tourneau C, et al: The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. *Ann Oncol* 29:30-35, 2018
19. Wardell CP, Fujita M, Yamada T, et al: Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. *J Hepatol* 68:959-969, 2018
20. Vicentini C, Cantu C, Antonello D, et al: ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. *Pathol Res Pract*, 2018
21. Vaughn CP, Costa JL, Feilotter HE, et al: Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. *BMC Cancer* 18:828, 2018
22. Trombetta D, Graziano P, Scarpa A, et al: Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. *Oncotarget* 9:9661-9671, 2018
23. Tabbo F, Nottegar A, Guerrera F, et al: Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. *Hum Pathol*, 2018
24. Simbolo M, Vicentini C, Ruzzenente A, et al: Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. *Sci Rep* 8:7119, 2018
25. Simbolo M, Vicentini C, Mafficini A, et al: Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. *Virchows Arch*, 2018
26. Scarpa A, Real FX, Luchini C: Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management. *Gut* 67:1561-1563, 2018
27. Scarpa A, Mafficini A: Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. *Gut* 67:399-400, 2018
28. Riva G, Pea A, Pilati C, et al: Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma. *World J Gastrointest Oncol* 10:317-327, 2018

29. Rindi G, Klimstra DS, Abedi-Ardekani B, et al: A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Mod Pathol* 31:1770-1786, 2018
30. Rindi G, Klersy C, Albarello L, et al: Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. *Neuroendocrinology* 107:375-386, 2018
31. Rimbasi M, Crino SF, Gasbarrini A, et al: EUS-guided fine-needle tissue acquisition for solid pancreatic lesions: Finally moving from fine-needle aspiration to fine-needle biopsy? *Endosc Ultrasound* 7:137-140, 2018
32. Resovi A, Bani MR, Porcu L, et al: Soluble stroma-related biomarkers of pancreatic cancer. *EMBO Mol Med*, 2018
33. Remo A, Manfrin E, Parcesepe P, et al: Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. *Mol Cancer Res*, 2018
34. Rapa I, Votta A, Gatti G, et al: High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. *Oncotarget* 9:27535-27546, 2018
35. Pilotto S, Sperduti I, Leuzzi G, et al: Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. *J Thorac Oncol* 13:568-575, 2018
36. Peraldo-Neia C, Ostano P, Cavalloni G, et al: Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. *BMC Genomics* 19:440, 2018
37. Pelosi G, Bianchi F, Dama E, et al: Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. *Virchows Arch*, 2018
38. Pea A, Yu J, Marchionni L, et al: Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. *Ann Surg*, 2018
39. Pea A, Riva G, Bernasconi R, et al: Ampulla of Vater carcinoma: Molecular landscape and clinical implications. *World J Gastrointest Oncol* 10:370-380, 2018
40. Paiella S, Salvia R, De Pastena M, et al: Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. *Pancreatol*, 2018
41. Paiella S, Malleo G, Cataldo I, et al: Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. *Langenbecks Arch Surg* 403:213-220, 2018
42. Noe M, Pea A, Luchini C, et al: Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. *Mod Pathol*, 2018
43. Moro M, Caiola E, Ganzinelli M, et al: Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC). *J Thorac Oncol*, 2018
44. Molina-Montes E, Gomez-Rubio P, Marquez M, et al: Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. *Int J Epidemiol*, 2018
45. Milione M, Maisonneuve P, Pellegrinelli A, et al: Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. *Endocr Relat Cancer* 25:583-593, 2018
46. Marchegiani G, Landoni L, Andrianello S, et al: Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? *Neuroendocrinology*, 2018
47. Marchegiani G, Andrianello S, Borin A, et al: Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas. *Surgery*, 2018
48. Malpeli G, Barbi S, Tosadori G, et al: MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. *Oncotarget* 9:29753-29771, 2018
49. Mafficini A, Scarpa A: Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium. *J Endocrinol*, 2018
50. Mafficini A, Amato E, Cataldo I, et al: Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. *Ann Surg* 267:149-156, 2018
51. Luchini C, Veronese N, Nottegar A, et al: Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. *Virchows Arch*, 2018
52. Luchini C, Pea A, Yu J, et al: Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. *Mod Pathol*, 2018
53. Luchini C, Cros J, Pea A, et al: PD-1, PD-L1 and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. *Hum Pathol*, 2018
54. Lampis A, Carotenuto P, Vlachogiannis G, et al: MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. *Gastroenterology* 154:1066-1079 e5, 2018
55. Iacovelli R, Ciccarese C, Mosillo C, et al: Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. *Target Oncol*, 2018
56. Gkoutakos A, Pilotto S, Mafficini A, et al: Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. *Carcinogenesis*, 2018
57. Fiore A, Ugel S, De Sanctis F, et al: Induction of immunosuppressive functions and NF-kappaB by FLIP in monocytes. *Nat Commun* 9:5193, 2018
58. European Study Group on Cystic Tumours of the Pancreas, Del Chiaro M, Besselink M, et al: European evidence-based guidelines on pancreatic cystic neoplasms. *Gut*, 2018

59. Eccher A, Brunelli M, Pantanowitz L, et al: Innovation in Transplantation: The Digital Era. *J Pathol Inform* 9:33, 2018
60. Del Curatolo A, Conciatori F, Cesta Incani U, et al: Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. *J Exp Clin Cancer Res* 37:140, 2018
61. De Robertis R, Maris B, Cardobi N, et al: Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? *Eur Radiol*, 2018
62. Crino SF, Bernardoni L, Gabbrielli A, et al: Beyond Pancreatic Cyst Epithelium: Evidence of Ovarian-Like Stroma in EUS-Guided Through-the-Needle Micro-Forceps Biopsy Specimens. *Am J Gastroenterol*, 2018
63. Cima L, Brunelli M, Parwani A, et al: Validation of Remote Digital Frozen Sections for Cancer and Transplant Intraoperative Services. *J Pathol Inform* 9:34, 2018
64. Chattaragada MS, Riganti C, Sassoe M, et al: FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. *Oncogene* 37:697-709, 2018
65. Brunetti O, Aprile G, Marchetti P, et al: Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. *Pancreas*, 2018
66. Bauer AS, Nazarov PV, Giese NA, et al: Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. *Int J Cancer* 142:1010-1021, 2018